| Abstract [eng] |
SUMMARY Objective. To evaluate and compare the efficacy and safety of intragastric balloon in the treatment of adult obesity. To present and analyze a clinical case. Methods. In this systematic literature review scientific articles were selected by searching PubMed and WebOfScience databases. English-language publications describing intragastric balloon therapy between 2017 and 2022 were retrieved. The efficacy of treatment was evaluated by calculating the pooled mean outcomes in accordance with duration of therapy, the intragastric balloon system used and the patients' baseline body mass index. Safety was described in terms of mild side-effects, premature intragastric balloon removal and mortality. Results. The systematic literature review included 35 publications. The pooled mean of excess body weight loss was 65.43 % at 4 months, 57.61 % at 6 months and 54.19 % at 12-18 months. The pooled mean total body weight loss was 14.09 % at 4 months, 16.2 % at 6 months and 19.71 % at 12-18 months. No significant difference was observed between the intragastric balloon systems used, with the mean %EBWL and %TBWL for Orbera patients being 40.89 % and 13.6 %, and the mean %EBWL and %TBWL for Elipse patients being 65.43 % and 13.9 %. The most common mild adverse symptoms after intragastric balloon therapy occurred during the first week, including nausea, vomiting, abdominal pain, and weakness. In 4.6 % of patients, the intragastric balloon was removed prematurely, the main reasons being severe adverse events that did not diminish with medication, pregnancy, and patient preference. 4 deaths (0.0002 %) occurred during the early treatment period. The prevalence of comorbidities – type 2 diabetes, arterial hypertension, hyperlipidaemia – decreased after the therapy, from 14,6 % to 66 % of these patients’ achieved remission of these diseases. Conclusions. Intragastric balloon therapy is a safe and effective option for the short-term treatment of adult obesity. It is an appropriate choice for initial treatment or as an intermediate therapy before surgical interventions. Intragastric balloon therapy achieves significant weight loss, leading to a reduction in morbidity and remission of comorbidities. Keywords: obesity, intragastric balloon, obesity treatment, treatment efficacy, treatment safety. |
